Vivo Capital
Crossover fundPalo Alto · Seed–Late Stage · 25 people tracked
Also known as VIVO CAPITAL LLC
Investment thesis
Vivo Capital is a global healthcare specialist deploying a multi-strategy investment platform across venture capital, private equity, and public equity. The firm targets the healthcare industry to broaden access to care and to catalyze innovation and growth, using what it calls an 'Ecosystem Strategy.' With over three decades in business, it has backed companies through numerous IPOs, M&As, and regulatory approvals across a broad global investment portfolio.
Source: firm website, verified Aug 3, 2026.
Team · 25 people
from public directories
What they invest in
from 46 of 102 portfolio companiesBiotech ×35Healthtech ×23Medical Devices ×15Digital Health ×4Deep Tech ×3Enterprise Software ×2SaaS ×2Advanced Manufacturing ×1
HQs:United States×41Australia×1Canada×1Denmark×1
Investments · 102 tracked
founders shown can be your intro pathBiotechSouth San Francisco, US
Julian Symons(Executive Officer)Lawrence M. Blatt(President and Chief Executive Officer)Lesley Ann Calhoun(Executive Officer)Hardean Achneck(Executive Officer)Carole Neuchterlein(Director)Jack Nielsen(Director)
Board seatJack Nielsen· per SEC Form D · $92.2M raise · filed Nov 2023
BiotechSan Diego, US
YunFei Zhu(Executive Officer)Steve Kaldor(Director)Mason Freeman(Director)Wendell Wierenga(Director)Richard Scott Struthers(Executive Officer, Director)Mahendra Shah(Director)
Board seatJack Nielsen· per SEC Form D · $65M raise · filed Feb 2018
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Jeffrey Aronin(Director)Aaron Royston(Director)Dr. Andreas Wicki(Director)Jack Nielsen(Director)
Board seatJack Nielsen· per SEC Form D · $50M raise · filed Aug 2019
HealthtechSalt Lake City, US
Mansoor Mirza(Director)Marcus Wilson(Director)Ryan M. Trimble(Director)Joseph Siletto(Director)Dennis B. Farrar(Director)Douglas Fisher(Executive Officer)
Board seatJoseph Siletto· per SEC Form D
Aadi Bioscience is a commercial-stage biopharmaceutical company developing therapies for cancer patients with mTOR pathway driver alterations, with an initial focus on advanced malignant PEComa, an ultra-rare cancer.
BiotechHealthtechMorristown, US
Baiteng Zhao(Director)Scott Giacobello(Executive Officer)Caley Castelein(Director)Richard Maroun(Director)Bryan Ball(Executive Officer)Behzad Aghazadeh(Director)
BiotechVancouver, B.C.
Cindy Jacobs(Executive Officer, Director)Anthony Clarke(Executive Officer)Bridget Martell(Director)Martin Mattingly(Director)Jaime Xinos(Executive Officer)Vaughn Himes(Director)
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)Kevin Balthaser(Executive Officer)Kamil Ali-Jackson(Executive Officer)
Alto Neuroscience is a precision psychiatry company developing personalized drug treatments for people with neuropsychiatric conditions, using neuroscience research and clinical data to match patients to appropriate therapies.
BiotechDigital HealthMental HealthMountain View, US
Adam Savitz(Executive Officer)Amit Etkin(Founder)Nicholas C. Smith(Executive Officer)Gwill York(Director)Husseini Manji(Director)Christopher Nixon Cox(Director)
Cambridge, US
Instil Bio is a biotechnology company that identifies and develops therapeutic opportunities, with a focus on cancer therapies.
BiotechDallas, US
Nimish Shah(Director)Bronson Crouch(Chief Executive Officer & Chairman of the Board)Jack Nielsen(Director)Gwen Binder(Director)Kent McGaughy(Director)Neil Gibson(Director)
BiotechLondon
Dr. Peter Fellner(Chairman)Richard Jones(Chief Financial Officer)Kunal Kashyap(Non-Executive Director)Paul Blackburn(Non-Executive Director)John Richard(Head of Corporate Development and Co-Founder)Dr. Denise Scots-Knight(Chief Executive Officer and Co-Founder)
Minerva Neurosciences is a biopharmaceutical company developing therapies for central nervous system disorders, including schizophrenia, insomnia, major depressive disorder, and Parkinson's disease.
BiotechWaltham, US
Jan Van Heek(Director)Joseph Reilly(Executive Officer)Nico Vandervelpen(Director)Geoff Race(Executive Officer)Fred Ahlholm(Executive Officer)Remy Luthringer(Executive Officer, Director)
HealthtechVenice, US
Lawrence Steinman(Director)Tiago Reis Marques(Director)Israel Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
Tenax Therapeutics is a clinical-stage pharmaceutical company developing drug therapies for cardiovascular and pulmonary vascular diseases, including heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension.
BiotechDigital HealthHealthtechChapel Hill, US
Stuart Rich(Chief Medical Officer)Lawrence R. Hoffman(Interim Chief Financial Officer)Christopher T. Giordano(President and Chief Executive Officer)Michael B. Jebsen(Executive Officer)Ronald R. Blanck(Director)Gregory Pepin(Director)
BiotechWaltham, US
JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)
Neocis is a company in the dental healthcare technology space, serving US healthcare professionals.
HealthtechMedical DevicesRoboticsMiami, US
Alon Mozes(CEO & Co-Founder)inJuan Salcedo(Engineering Fellow & Co-Founder)inDennis Moses(Chief Technical Officer)inAndres Carrillo(VP of Product)inJorge Fernandes(VP of Quality & Regulatory)inGabe Goldberg(VP of Marketing)in
ABK Biomedical is a clinical-stage medical device company developing imageable microsphere products for treating cancer, including Eye90 microspheres for Y90 radioembolization in liver cancer and Easi-Vue embolic microspheres for embolization of arteriovenous malformations and hypervascular tumors.
BiotechHealthtechMedical DevicesHalifax, CA
Anthony Headley(Executive Officer)Gary Donofrio(Executive Officer)Michael Mangano(Executive Officer, Director)David Dobrowsky(Executive Officer)Keten Patel(Director)Lucy Bataneant(Executive Officer)
Board seatJoseph Siletto· per SEC Form D · $2.6M raise · filed Nov 2025
BiotechSan Diego, US
Jason Liu(Director)Yuh-geng Tsay(Director)Francois Ferre(Director)Jorge Garces(Executive Officer)Ann Kessler(Director)David Nikodem(Director)
Board seatYuh-geng Tsay· per SEC Form D · $3M raise · filed Mar 2018
Amyris uses microbes to convert plant-derived sugars into engineered molecules at scale, offering custom renewable chemistry for industrial partners.
Advanced ManufacturingBiotechCleantechNew MaterialsEmeryville, US
NICHOLAS KHADDER(Executive Officer)NEIL WILLIAMS(Director)FERNANDO REINACH(Director)CAROLE PIWNICA(Director)RAFFI ASADORIAN(Executive Officer)JOEL CHERRY(Executive Officer)
Board seatFrank Kung· per SEC Form D · $38.1M raise · filed Apr 2018
Pleasanton, US
Chih-Ping Liu(Executive Officer, Director, Promoter)Edgar G Engleman(Director)
Board seatEdgar G. Engleman· per SEC Form D · $93.5M raise · filed Jan 2021
HealthtechRedwood City, US
Gina Phelps(Executive Officer)Stephen N. Kirnon(Director)Ernest Mario(Director)David D. O'Toole(Executive Officer)William James Alexander(Director)Steinar Engelsen(Director)
Board seatEdgar G. Engleman· per SEC Form D · $3.7M raise · filed Mar 2015
BiotechSanta Clara, US
Nina Kjellson(Director)Ed Engleman(Director)Jeffrey Glenn(Director)David Cory(Executive Officer, Director)
Board seatEdgar G. Engleman· per SEC Form D · $3M raise · filed Apr 2016
Lumithera develops Valeda PBM, an FDA-authorized photobiomodulation light delivery system for treating dry age-related macular degeneration (AMD) to improve and maintain vision.
HealthtechMedical DevicesAtlanta, US
Ronald P. Thiboutot(Director)William D. McPhee(Director)John G. Edwards(Executive Officer, Director)
BoardGregory R. Jackson(Director)
Board seatNathan DauJack Nielsen· per SEC Form D · $22M raise · filed Dec 2021
Houston, US
Board seatJoseph Siletto· per SEC Form D · $45M raise · filed Jul 2020
Readcoor develops in situ spatial profiling technology using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections.
BiotechDeep TechHardwareHealthtechCambridge, US
Yuh-Geng Tsay(Director)Thomas Grogan(Director)Victor Tong(Director)Richard Terry(Executive Officer, Director)Evan Daugharthy(Cofounder)
Board seatYuh-geng Tsay· per SEC Form D · $23M raise · filed Sep 2016
Plano, US
Board seatJack Nielsen· per SEC Form D · $50M raise · filed Jun 2020
HealthtechWest Valley City, US
Jeffrey Gladden(Dr. Gladden is a manager of the issuer.)David Bearss(Mr. Bearss is a manager of the issuer.)John Lippert(Executive Officer, Director)Rick Randall(Mr. Randall is a manager of the issuer.)Stacy Lippert(Executive Officer, Director)Jerry Henley(Mr. Henley is a manager of the issuer.)
Board seatNathan DauJoseph Siletto· per SEC Form D
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Board seatJoseph Siletto· per SEC Form D · $112M raise · filed Sep 2021
BiotechNew York, US
Martin Vogelbaum(Executive Officer, Director)Ross Levine(Director)Ramy Farid(Director)Scott Platshon(Director)
Bonum Therapeutics is an early-stage biotechnology company.
BiotechSeattle, US
Samuel Bjork(Director)Neela Patel(Executive Officer)Diane Hollenbaugh(Executive Officer)Samuel Blackman(Director)John Mulligan(Executive Officer, Director, Promoter)Karl Handelsman(Director)
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Steve Elms(Director)Dan Burgess(Director)Scott Rocklage(Director)Ted Schroeder(Director)Kevin Forrest(Executive Officer)
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical Devices
BoardMichael Kavanaugh(Founding Advisor)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 4
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Vivo Capital IXLPs: California State Teachers' Retirement System, Baltimore City Employees' Retirement System | 2019 | — | 18.8% | 1.73x | 0.70x |
| Vivo Opportunity Fund, LPLPs: Empire State Development – New York Ventures | 2018 | — | — | 1.84x | 1.84x |
| Vivo Capital Fund VIII, L.P.LPs: California State Teachers' Retirement System | 2015 | — | 14.9% | 1.96x | 1.51x |
| Vivo Capital Surplus Fund VIII, L.P.LPs: California State Teachers' Retirement System | 2015 | — | 15.9% | 2.01x | 1.55x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ14 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Vivo Capital invest at?
- Vivo Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Vivo Capital's typical check size?
- Vivo Capital typically writes checks of $10M – $50M.
- What sectors does Vivo Capital focus on?
- Vivo Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Vivo Capital located?
- Vivo Capital is headquartered in Palo Alto, US.
- Does Vivo Capital lead rounds?
- Yes, Vivo Capital leads investment rounds.
Co-investors · 24
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Qiming Venture Partners is a China-focused venture capital firm that backs entrepreneurs across technology and healthcare sectors, taking active board and strategic roles from early rounds through public listings.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
▶12 more co-investors
Versant VenturesKurma PartnersVida VenturesaMoonToba CapitalEarlybird Venture CapitalDeerfield Management CompanyDomain AssociatesThird Rock VenturesMPM BioImpactCatalio Capital ManagementCincyTech
Firms observed investing alongside Vivo Capital, from public investor directories. Shared companies are the overlap with Vivo Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Portfolia operates thematic venture capital funds designed for women investors, backing companies in areas such as women's health, longevity, active aging, greentech, and fintech, while offering an educational and community-driven investing experience.